Fifty five children with nocturnal enuresis referred to a hospital enuresis clinic entered a controlled trial to compare the efficacy of one month and three month courses of intranasal desmopressin (Desmospray). There was no significant difference in outcome between the two groups. Overall 36% improved by at least two dry nights/week during treatment, but only five children (18%) in the one mon...

Monotherapeutic strategies often have only partial success in primary nocturnal enuresis (PNE). This analysis evaluated whether adjuvant treatment strategies improve outcomes. PNE children were submitted to a distinct therapeutic strategy including urotherapy (behavioral modifications), a first-line and, if necessary, a second-line treatment period. Outcome was the relief of bedwetting, the fol...

A 60-year-old man was prescribed oral desmopressin (1-deamino-8-D-arginine vasopressin acetate trihydrate; DDAVP) for nocturnal polyuria. One week after starting to take desmopressin, he frequently felt chest pain while resting. Coronary angiography revealed no organic stenosis; however, an acetylcholine provocation test showed severe coronary spasm with ST elevation. He was diagnosed with coro...

Therapy for mild hemophilia A consists of desmopressin acetate (1-deamino[8-D-arginine]-vasopressin; desmopressin; DDAVP), which increases factor VIII and von Willebrand factor antigen (VWF:Ag) levels two-fold to six-fold through endogenous release from endothelial cells [1]. The effect of desmopressin varies between patients, and has been suggested to depend on the hemophilia-causing mutation ...

BACKGROUND Desmopressin-induced release of tissue plasminogen activator from endothelial cells may explain the absence of its hemostatic effect in patients undergoing cardiac surgery. Prior administration of the antifibrinolytic drug tranexamic acid might unmask such an effect, and combination therapy might thereby improve postoperative hemostasis. METHODS AND RESULTS A double-blinded design ...

Seven mild or moderate hemophilia A and 4 von Willebrand’s disease patients were infused with desmopressin (DDA VP), a synthetic analogue vasopressin, prior to their dental treatment. An assessment of the individual’s response to desmopressin was performed initially in all patients using a dose of 0.3 ~g/kg intravenously. This procedure resulted in a mean 4.7-fold increase in plasma Factor VIII...

IN T RODUC T ION Desmopressin (1-desamino-8-D-arginine vasopressin), Figure 1, (trade names: DDAVP, Stimate, Minirin) is a peptide containing nine amino acids, a form of the normal human hormone arginine vasopressin that reduces urine production. It may be taken nasally, intravenously, or as a tablet. Desmopressin is most commonly prescribed for the treatment of diabetes insipidus or nocturnal ...

House dust mite allergens express protease activity and it has been suggested that this property has pathogenic effects by increasing airway absorption. In accordance, house dust mite allergens may increase mucosal permeability in vitro. The objective of the present study was to examine nasal absorption of desmopressin (1-deamino-8-D-arginine vasopressin) in patients with perennial house dust m...

OBJECTIVE Dilutional hyponatremia is a serious adverse effect of desmopressin, a vasopressin analog that is widely prescribed to manage monosymptomatic enuresis. The presentation of hyponatremia, largely related to cerebral dysfunction, can include severe signs like altered mental status and seizures. METHODS We reviewed the literature dealing with altered mental status or seizures in enureti...